Systematic review: Managing suboptimal treatment responses in autoimmune hepatitis with conventional and nonstandard drugs

Alimentary Pharmacology and Therapeutics

Volumn 36, Issue 8, 2012, Pages 691-707

  Selvarajah, V ^a   Montano Loza, A J ^a   Czaja, A J ^b  

^a UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; BUDESONIDE; CYCLOSPORIN; INFLIXIMAB; LIVER ANTIGEN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS;

ACNE; AKINETIC MUTISM; ALOPECIA; ANEMIA; ARTICLE; ASEPTIC NECROSIS; ATAXIA; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNE HEPATITIS; B CELL LYMPHOMA; BLINDNESS; BONE MARROW SUPPRESSION; CATARACT; CORTICOSTEROID INDUCED OSTEOPOROSIS; COUGHING; CRYOGLOBULINEMIA; CRYPTOCOCCAL MENINGITIS; CYTOPENIA; DIABETES MELLITUS; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FACE DISORDER; FACE EDEMA; FATIGUE; GINGIVA HYPERPLASIA; GINGIVITIS; GLAUCOMA; GLOMERULONEPHRITIS; GLUCOSE INTOLERANCE; HALLUCINATION; HEMOLYTIC UREMIC SYNDROME; HEMOPHILIA; HIP DISEASE; HIRSUTISM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFECTION; JAUNDICE; KIDNEY FAILURE; LEUKOENCEPHALOPATHY; LEUKOPENIA; LIVER CIRRHOSIS; LIVER NECROSIS; LOW DRUG DOSE; LUNG TOXICITY; MALIGNANT NEOPLASTIC DISEASE; MENTAL INSTABILITY; MONOTHERAPY; MUSCLE WEAKNESS; NAUSEA; NEPHROTIC SYNDROME; NEPHROTOXICITY; NEURALGIA; NEUROLOGIC DISEASE; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; OFF LABEL DRUG USE; OPPORTUNISTIC INFECTION; OSTEOPENIA; PANCREATITIS; PATIENT MONITORING; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROBABILITY; PROTEINURIA; PRURITUS; PSORIASIS; PSYCHOSIS; RELAPSE; RHEUMATOID ARTHRITIS; RISK FACTOR; SALVAGE THERAPY; SCORING SYSTEM; SEIZURE; SIDE EFFECT; SPINE DISEASE; SQUAMOUS CELL CARCINOMA; STOMATITIS; STRIA; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE; TREMOR; VIRUS INFECTION; VIRUS REACTIVATION; VOMITING; WEIGHT GAIN; WOUND HEALING IMPAIRMENT;

AGE FACTORS; HEPATITIS, AUTOIMMUNE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; RECURRENCE; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE;

EID: 84866393237     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12042     Document Type: Article

References (148)

1. Czaja AJ, Manns MP,. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterology 2010; 139: 58-72.
2. Cook GC, Mulligan R, Sherlock S,. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971; 40: 159-85.
3. Soloway RD, Summerskill WH, Baggenstoss AH, et al,. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972; 63: 820-33.
4. Murray-Lyon IM, Stern RB, Williams R,. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973; 1: 735-7.
5. Manns MP, Czaja AJ, Gorham JD, et al,. American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. Hepatology 2010; 51: 2193-213.
6. Schalm SW, Ammon HV, Summerskill WH,. Failure of customary treatment in chronic active liver disease: causes and management. Ann Clin Res 1976; 8: 221-7.
7. Montano-Loza AJ, Carpenter HA, Czaja AJ,. Features associated with treatment failure in type 1 autoimmune hepatitis and predictive value of the model of end-stage liver disease. Hepatology 2007; 46: 1138-45.
8. Yeoman AD, Westbrook RH, Zen Y, et al,. Early predictors of corticosteroid treatment failure in icteric presentations of autoimmune hepatitis. Hepatology 2011; 53: 926-34.
9. Montano-Loza AJ, Carpenter HA, Czaja AJ,. Predictive factors for hepatocellular carcinoma in type 1 autoimmune hepatitis. Am J Gastroenterol 2008; 103: 1944-51.
10. Sanchez-Urdazpal L, Czaja AJ, van Hoek B, Krom RA, Wiesner RH,. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology 1992; 15: 215-21.
11. Czaja AJ, Carpenter HA,. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology 2006; 43: 532-8.
12. Ichai P, Duclos-Vallee JC, Guettier C, et al,. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl 2007; 13: 996-1003.
13. Czaja AJ, Rakela J, Ludwig J,. Features reflective of early prognosis in corticosteroid treated severe autoimmune chronic active hepatitis. Gastroenterology 1988; 95: 448-53.
14. Czaja AJ,. Autoantibodies as prognostic markers in autoimmune liver disease. Dig Dis Sci 2010; 55: 2144-61.
15. Czaja AJ, Shums Z, Norman GL,. Frequency and significance of antibodies to soluble liver antigen/liver pancreas in variant autoimmune hepatitis. Autoimmunity 2002; 35: 475-83.
16. Ma Y, Okamoto M, Thomas MG, et al,. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002; 35: 658-64.
17. Czaja AJ, Donaldson PT, Lohse AW,. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. Am J Gastroenterol 2002; 97: 413-9.
18. Liaskos C, Bogdanos DP, Rigopoulou EI, et al,. Antibody responses specific for soluble liver antigen co-occur with Ro-52 autoantibodies in patients with autoimmune hepatitis (abstract). J Hepatol 2007; 46: S250.
19. Montano-Loza AJ, Shums Z, Norman GL, Czaja AJ,. Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis. Liver Int 2012; 32: 85-92.
20. Baeres M, Herkel J, Czaja AJ, et al,. Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut 2002; 51: 259-64.
21. Alvarez F, Berg PA, Bianchi FB, et al,. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999; 31: 929-38.
22. Horsmans Y, Piret A, Brenard R, Rahier J, Geubel AP,. Autoimmune chronic active hepatitis responsive to immunosuppressive therapy evolving into a typical primary biliary cirrhosis syndrome: a case report. J Hepatol 1994; 21: 194-8.
23. Abdo AA, Bain VG, Kichian K, Lee SS,. Evolution of autoimmune hepatitis to primary sclerosing cholangitis: a sequential syndrome. Hepatology 2002; 36: 1393-9.
24. Rabinovitz M, Demetris AJ, Bou-Abboud CF, Van Thiel DH,. Simultaneous occurrence of primary sclerosing cholangitis and autoimmune chronic active hepatitis in a patient with ulcerative colitis. Dig Dis Sci 1992; 37: 1606-11.
25. McNair ANB, Moloney M, Portmann BC, Williams R, McFarlane IG,. Autoimmune hepatitis overlapping with primary sclerosing cholangitis in 5 cases. Am J Gastroenterol 1998; 93: 777-84.
26. Czaja AJ, Magrin S, Fabiano C, et al,. Hepatitis C virus infection as a determinant of behavior in type 1 autoimmune hepatitis. Dig Dis Sci 1995; 40: 33-40.
27. DePinho RA, Goldberg CS, Lefkowitch JH,. Azathioprine and the liver. Evidence favoring idiosyncratic, mixed cholestatic-hepatocellular injury in humans. Gastroenterology 1984; 86: 162-5.
28. Hay JE, Czaja AJ, Rakela J, Ludwig J,. The nature of unexplained chronic aminotransferase elevations of a mild to moderate degree in asymptomatic patients. Hepatology 1989; 9: 193-7.
29. Schramm C, Weiler-Normann C, Wiegard C, Hellweg S, Müller S, Lohse AW,. Treatment response in patients with autoimmune hepatitis. Hepatology 2010; 52: 2247-8.
30. Lohse A, Mieli-Vergani G,. Autoimmune hepatitis. J Hepatol 2011; 55: 171-82.
31. Gleeson D, Heneghan MA,; British Society of Gastroenterology. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut 2011; 60: 1611-29.
32. Czaja AJ, Davis GL, Ludwig J, Taswell HF,. Complete resolution of inflammatory activity following corticosteroid treatment of HBsAg-negative chronic active hepatitis. Hepatology 1984; 4: 622-7.
33. Czaja AJ,. Rapidity of treatment response and outcome in type 1 autoimmune hepatitis. J Hepatol 2009; 51: 161-7.
34. Montano-Loza AJ, Carpenter HA, Czaja AJ,. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse. Am J Gastroenterol 2007; 102: 1005-12.
35. Czaja AJ, Ludwig J, Baggenstoss AH, Wolf A,. Corticosteroid-treated chronic active hepatitis in remission: uncertain prognosis of chronic persistent hepatitis. N Engl J Med 1981; 304: 5-9.
36. Czaja AJ,. Late relapse of type 1 autoimmune hepatitis after corticosteroid withdrawal. Dig Dis Sci 2010; 55: 1761-9.
37. Roberts SK, Therneau TM, Czaja AJ,. Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology 1996; 110: 848-57.
38. Davis GL, Czaja AJ, Ludwig J,. Development and prognosis of histologic cirrhosis in corticosteroid-treated hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology 1984; 87: 1222-7.
39. Miyake Y, Iwasaki Y, Terada R, et al,. Persistent normalization of serum alanine aminotransferase levels improves the prognosis of type 1 autoimmune hepatitis. J Hepatol 2005; 43: 951-7.
40. Verma S, Gunuwan B, Mendler M, Govindrajan S, Redeker A,. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol 2004; 99: 1510-6.
41. Czaja AJ, Carpenter HA,. Histological features associated with relapse after corticosteroid withdrawal in type 1 autoimmune hepatitis. Liver Int 2003; 23: 116-23.
42. Werner M, Wallerstedt S, Lindgren S, et al,. Characteristics and long-term outcome of patients with autoimmune hepatitis related to the initial treatment response. Scand J Gastroenterol 2010; 45: 457-67.
43. Gueguen P, Dalekos G, Nousbaum JB, et al,. Double reactivity against actin and alpha-actinin defines a severe form of autoimmune hepatitis type 1. J Clin Immunol 2006; 26: 495-505.
44. Oikonomou KG, Zachou K, Dalekos GN,. Alpha-actinin: a multidisciplinary protein with important role in B-cell driven autoimmunity. Autoimmun Rev 2011; 10: 389-96.
45. Zachou K, Oikonomou K, Renaudineau Y, et al,. Anti-α actinin antibodies as new predictors of response to treatment in autoimmune hepatitis type 1. Aliment Pharmacol Ther 2012; 35: 116-25.
46. Czaja AJ,. Advances in the current treatment of autoimmune hepatitis. Dig Dis Sci 2012; 57: 1996-2010.
47. Stellon AJ, Keating JJ, Johnson PJ, McFarlane IG, Williams R,. Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. Hepatology 1988; 8: 781-4.
48. Johnson PJ, McFarlane IG, Williams R,. Azathioprine for long-term maintenance of remission in autoimmune hepatitis. N Engl J Med 1995; 333: 958-63.
49. Czaja AJ,. Low-dose corticosteroid therapy after multiple relapses of severe HBsAg-negative chronic active hepatitis. Hepatology 1990; 11: 1044-9.
50. Seela S, Sheela H, Boyer JL,. Autoimmune hepatitis type 1: safety and efficacy of prolonged medical therapy. Liver Int 2005; 25: 734-9.
51. Czaja AJ, Wolf AM, Baggenstoss AH,. Laboratory assessment of severe chronic active liver disease during and after corticosteroid therapy: correlation of serum transaminase and gamma globulin levels with histologic features. Gastroenterology 1981; 80: 687-92.
52. Czaja AJ,. Safety issues in the management of autoimmune hepatitis. Expert Opin Drug Saf 2008; 7: 319-33.
53. Uribe M, Go VL, Kluge D,. Prednisone for chronic active hepatitis: pharmacokinetics and serum binding in patients with chronic active hepatitis and steroid major side effects. J Clin Gastroenterol 1984; 6: 331-5.
54. Summerskill WHJ, Korman MG, Ammon HV, Baggenstoss AH,. Prednisone for chronic active liver disease: dose titration, standard dose and combination with azathioprine compound. Gut 1975; 16: 876-83.
55. Maddocks JL, Lennard L, Amess J, Amos R, Thomas RM,. Azathioprine and severe bone marrow depression. Lancet 1986; 1: 156.
56. Ben Ari Z, Mehta A, Lennard L, Burroughs AK,. Azathioprine induced myelosuppression due to thiopurine methyltransferase deficiency in a patient with autoimmune hepatitis. J Hepatol 1995; 23: 351-4.
57. Bacon BR, Treuhaft WH, Goodman AM,. Azathioprine-induced pancytopenia. Occurrence in two patients with connective-tissue diseases. Arch Intern Med 1981; 141: 223-6.
58. Tragnone A, Bazzocchi G, Aversa G, et al,. Acute pancreatitis after azathioprine treatment for ulcerative colitis. Ital J Gastroenterol 1996; 28: 102-4.
59. Wang KK, Czaja AJ, Beaver SJ, Go VL,. Extrahepatic malignancy following long-term immunosuppressive therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. Hepatology 1989; 10: 39-43.
60. Ziegler TR, Fernandez-Estivariz C, Gu LH, et al,. Severe villus atrophy and chronic malabsorption induced by azathioprine. Gastroenterology 2003; 124: 1950-7.
61. Vernier-Massouille G, Cosnes J, et al,. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut 2007; 56: 1404-9.
62. Rosenkrantz JG, Githens JH, Cox SM, Kellum DL,. Azathioprine (Imuran) and pregnancy. Am J Obstet Gynecol 1967; 97: 387-94.
63. de Boer NK, Jarbandhan SV, de Graaf P, et al,. Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites. Am J Gastroenterol 2006; 101: 1390-2.
64. Heneghan MA, Norris SM, O'Grady JG, et al,. Management and outcome of pregnancy in autoimmune hepatitis. Gut 2001; 48: 97-102.
65. Samuel D, Riordan S, Strasser S, et al,. Severe autoimmune hepatitis first presenting in the early post partum period. Clin Gastroenterol Hepatol 2004; 2: 622-4.
66. Schramm C, Herkel J, Beuers U, et al,. Pregnancy in autoimmune hepatitis: outcome and risk factors. Am J Gastroenterol 2006; 101: 556-60.
67. Werner M, Bjornsson E, Prytz H, et al,. Autoimmune hepatitis among fertile women: strategies during pregnancy and breastfeeding? Scand J Gastroenterol 2007; 42: 986-91.
68. Francella A, Dyan A, Bodian C, et al,. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 2003; 124: 9-17.
69. Montano-Loza AJ, Carpenter HA, Czaja AJ,. Consequences of treatment withdrawal in type 1 autoimmune hepatitis. Liver Int 2007; 27: 507-15.
70. Czaja AJ, Beaver SJ, Shiels MT,. Sustained remission after corticosteroid therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology 1987; 92: 215-9.
71. Czaja AJ, Menon KV, Carpenter HA,. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology 2002; 35: 890-7.
72. McFarlane IG, Hegarty JE, McSorley CG, et al,. Antibodies to liver-specific protein predict outcome of treatment withdrawal in autoimmune chronic active hepatitis. Lancet 1984; 2: 954-6.
73. Czaja AJ, Pfeifer KD, Decker RH, Vallari AS,. Frequency and significance of antibodies to asialoglycoprotein receptor in type 1 autoimmune hepatitis. Dig Dis Sci 1996; 41: 1733-40.
74. Hausdorf G, Roggenbuck D, Feist E, et al,. Autoantibodies to asialoglycoprotein receptor (ASGPR) measured by a novel ELISA-revival of a disease-activity marker in autoimmune hepatitis. Clin Chim Acta 2009; 408: 19-24.
75. McFarlane IG,. The relationship between autoimmune markers and different clinical syndromes in autoimmune hepatitis. Gut 1998; 42: 599-602.
76. Manns MP, Woynarowski M, Kreisel W, et al,. European AIH-BUC-Study Group. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology 2010; 139: 1198-206.
77. Czaja AJ, Lindor KD,. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology 2000; 119: 1312-6.
78. Heneghan MA, Al-Chalabi T, McFarlane IG,. Cost-effectiveness of pharmacotherapy for autoimmune hepatitis. Expert Opin Pharmacother 2006; 7: 145-56.
79. Manns MP,. Autoimmune hepatitis: the dilemma of rare diseases. Gastroenterology 2011; 140: 1874-6.
80. Czaja AJ,. Current and future treatments of autoimmune hepatitis. Expert Rev Gastroenterol Hepatol 2009; 3: 269-91.
81. Czaja AJ,. Promising pharmacological, molecular and cellular treatments of autoimmune hepatitis. Curr Pharm Des 2011; 17: 3120-40.
82. Czaja AJ,. Nonstandard drugs and feasible new interventions for autoimmune hepatitis. Part- I. Inflamm Allergy Drug Targets 2012 [Epub ahead of print].
83. Mistilis SP, Vickers CR, Darroch MH, McCarthy SW,. Cyclosporin, a new treatment for autoimmune chronic active hepatitis. Med J Aust 1985; 143: 463-5.
84. Hyams JS, Ballow M, Leichtner AM,. Cyclosporine treatment of autoimmune chronic active hepatitis. Gastroenterology 1987; 93: 890-3.
85. Person JL, McHutchison JG, Fong TL, Redeker AG,. A case of cyclosporine-sensitive, steroid-resistant, autoimmune chronic active hepatitis. J Clin Gastroenterol 1993; 17: 317-20.
86. Jackson LD, Song E,. Cyclosporin in the treatment of corticosteroid resistant autoimmune chronic active hepatitis. Gut 1995; 36: 459-61.
87. Sherman KE, Narkewicz M, Pinto PC,. Cyclosporine in the management of corticosteroid-resistant type I autoimmune chronic active hepatitis. J Hepatol 1994; 21: 1040-7.
88. Fernandes NF, Redeker AG, Vierling JM, Villamil FG, Fong TL,. Cyclosporine therapy in patients with steroid resistant autoimmune hepatitis. Am J Gastroenterol 1999; 94: 241-8.
89. Malekzadeh R, Nasseri-Moghaddam S, Kaviani MJ, et al,. Cyclosporin A is a promising alternative to corticosteroids in autoimmune hepatitis. Dig Dis Sci 2001; 46: 1321-7.
90. Bechstein WO,. Neurotoxicity of calcineurin inhibitors: impact and clinical management. Transpl Int 2000; 13: 313-26.
91. Toledo Perdomo K, Navarro Cabello MD, Perez Saez MJ, et al,. Reversible acute encephalopathy with mutism, induced by calcineurin inhibitors after renal transplantation. J Nephrol 2012; doi: 10.5301/jn.5000080 [Epub ahead of print].
92. Van Thiel DH, Wright H, Carroll P, et al,. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol 1995; 90: 771-6.
93. Larsen FS, Vainer B, Eefsen M, Bjerring PN, Adel Hansen B,. Low-dose tacrolimus ameliorates liver inflammation and fibrosis in steroid refractory autoimmune hepatitis. World J Gastroenterol 2007; 13: 3232-6.
94. Tannous MM, Cheng J, Muniyappa K, et al,. Use of tacrolimus in the treatment of autoimmune hepatitis: a single centre experience. Aliment Pharmacol Ther 2011; 34: 405-7.
95. Spencer CM, Goa KL, Gillis JC,. Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 1997; 54: 925-75.
96. Scott LJ, McKeage K, Keam SJ, Plosker GL,. Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 2003; 63: 1247-97.
97. Sievers TM, Rossi SJ, Ghobrial RM, et al,. Mycophenolate mofetil. Pharmacotherapy 1997; 17: 1178-97.
98. Zachou K, Gatselis N, Papadamou G, et al,. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naïve patients. J Hepatol 2011; 55: 636-46.
99. Schuppan D, Herold C, Strobel D, Schneider H, Hahn E,. Successful treatment of therapy-refractory autoimmune hepatitis with mycophenolate mofetil (abstract). Hepatology 1998; 28: S1960.
100. Richardson PD, James PD, Ryder SD,. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000; 33: 371-5.
101. Inductivo-Yu I, Adams A, Gish RG, et al,. Mycophenolate mofetil in autoimmune hepatitis patients not responsive or intolerant to standard immunosuppressive therapy. Clin Gastroenterol Hepatol 2007; 5: 799-802.
102. Hlivko JT, Shiffman ML, Stravitz RT, et al,. A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis. Clin Gastroenterol Hepatol 2008; 6: 1036-40.
103. Hennes EM, Oo YH, Schramm C, et al,. Mycophenolate mofetil as second line therapy in autoimmune hepatitis? Am J Gastroenterol 2008; 103: 3063-70.
104. Chatur N, Ramji A, Bain VG, et al,. Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int 2005; 25: 723-7.
105. Sharzehi K, Huang MA, Schreibman IR, Brown KA,. Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy. Can J Gastroenterol 2010; 24: 588-92.
106. Baven-Pronk AM, Coenraad MJ, van Buuren HR, et al,. The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes. Aliment Pharmacol Ther 2011; 34: 335-43.
107. Schramm C, Lohse AW,. Role of mycophenolate mofetil in the treatment of autoimmune hepatitis. J Hepatol 2011; 55: 510-1.
108. Anderka MT, Lin AE, Abuelo DN, Mitchell AA, Rasmussen SA,. Reviewing the evidence for mycophenolate mofetil as a new teratogen: case report and review of the literature. Am J Med Genet A 2009; 149: 1241-8.
109. Klieger-Grossmann C, Chitayat D, Lavign S, et al,. Prenatal exposure to mycophenolate mofetil: an updated estimate. J Obstet Gynaecol Can 2010; 32: 794-7.
110. Lin AE, Singh KE, Strauss A, Nguyen S, Rawson K, Kimonis VE,. An additional patient with mycophenolate mofetil embryopathy: cardiac and facial analyses. Am J Med Genet A 2011; 155: 748-56.
111. Danielsson A, Prytz H,. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther 1994; 8: 585-90.
112. Wiegand J, Schüler A, Kanzler S, et al,. Budesonide in previously untreated autoimmune hepatitis. Liver Int 2005; 25: 927-34.
113. Csepregi A, Röcken C, Treiber G, et al,. Budesonide induces complete remission in autoimmune hepatitis. World J Gastroenterol 2006; 12: 1362-6.
114. Geier A, Gartung C, Dietrich CG, Wasmuth HE, Reinartz P, Matern S,. Side effects of budesonide in liver cirrhosis due to chronic autoimmune hepatitis: influence of hepatic metabolism versus portosystemic shunts on a patient complicated with HCC. World J Gastroenterol 2003; 9: 2681-5.
115. Hempfling W, Grunhage F, Dilger K, Reichel C, Beuers U, Sauerbruch T,. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology 2003; 38: 196-202.
116. Efe C, Ozaslan E, Kav T, et al,. Liver fibrosis may reduce the efficacy of budesonide in the treatment of autoimmune hepatitis and overlap syndrome. Autoimmun Rev 2012; 11: 330-4.
117. Czaja AJ,. Understanding the pathogenesis of autoimmune hepatitis. Am J Gastroenterol 2001; 96: 1224-31.
118. Czaja AJ,. Autoimmune hepatitis. Part A: pathogenesis. Expert Rev Gastroenterol Hepatol 2007; 1: 113-28.
119. Santos ES, Arosemena LR, Raez LE, et al,. Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of the literature. Liver Int 2006; 26: 625-9.
120. Evans JT, Shepard MM, Oates JC, Self SE, Reuben A,. Rituximab-responsive cryoglobulinemic glomerulonephritis in a patient with autoimmune hepatitis. J Clin Gastroenterol 2008; 42: 862-3.
121. Barth E, Clawson JA,. Case of autoimmune hepatitis treated with rituximab. Case Rep Gastroenterol 2010; 4: 502-9.
122. Carey EJ, Somaratne K, Rakela J,. Successful rituximab therapy in refractory autoimmune hepatitis and Evans syndrome. Rev Med Chil 2011; 139: 1484-7.
123. Burak KW, Williamson-Coffey S, Swain MG, et al,. Rituximab for refractory autoimmune hepatitis: interim results of a phase 1 study. Hepatology 2008; 48: S1093.
124. Wolach O, Shpilberg O, Lahav M,. Neutropenia after rituximab treatment: new insights on a late complication. Curr Opin Hematol 2012; 19: 32-8.
125. Mastroianni CM, Lichtner M, Citton R, et al,. Current trends in management of hepatitis B virus reactivation in the biologic therapy era. World J Gastroenterol 2011; 17: 3881-7.
126. Uettwiller F, Rigal E, Hoarau C,. Infections associated with monoclonal antibody and fusion protein therapy in humans. MAbs 2011; 3: 461-6.
127. Subramanian M, Manjunath R, Kilara N, Mohan Rao KN,. Rituximab-induced subacute interstitial pneumonitis: a case report and review of literature. J Cancer Res Ther 2010; 6: 344-6.
128. Ram R, Ben-Bassat I, Shpilberg O, Polliack A, Raanani P,. The late adverse events of rituximab therapy-rare but there!. Leuk Lymphoma 2009; 50: 1083-95.
129. Berger JR,. Progressive multifocal leukoencephalopathy and newer biological agents. Drug Saf 2010; 33: 969-83.
130. Lysandropoulos AP, Du Pasquier RA,. Demyelination as a complication of new immunomodulatory treatments. Curr Opin Neurol 2010; 23: 226-33.
131. Ferri C, Cacoub P, Mazzaro C, et al,. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmun Rev 2011; 11: 48-55.
132. Asrani SK, Leise MD, West CP, et al,. Use of sirolimus in liver transplant recipients with renal insufficiency: a systematic review and meta-analysis. Hepatology 2010; 52: 1360-70.
133. Sehgal SN,. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998; 31: 335-40.
134. Brown EJ, Albers MW, Shin TB, et al,. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature 1994; 369: 756-8.
135. Hay N, Sonenberg N,. Upstream and downstream of mTOR. Genes Dev 2004; 18: 1926-45.
136. Nikolaeva N, Bemelman FJ, Yong SL, van Lier RA, ten Berge IJ,. Rapamycin does not induce anergy but inhibits expansion and differentiation of alloreactive human T cells. Transplantation 2006; 81: 445-54.
137. Kerkar N, Dugan C, Rumbo C, et al,. Rapamycin successfully treats post-transplant autoimmune hepatitis. Am J Transplant 2005; 5: 1085-9.
138. Veroux M, Tallarita T, Corona D, D'Assoro A, Gurrieri C, Veroux P,. Sirolimus in solid organ transplantation: current therapies and new frontiers. Immunotherapy 2011; 3: 1487-97.
139. Augustine JJ, Bodziak KA, Hricik DE,. Use of sirolimus in solid organ transplantation. Drugs 2007; 67: 369-91.
140. Weiler-Normann C, Wiegard C, Schramm C, Lohse AW,. A case of difficult-to-treat autoimmune hepatitis successfully managed by TNF-alpha blockade. Am J Gastroenterol 2009; 104: 2877-8.
141. Burak KW, Urbanski SJ, Swain MG,. Successful treatment of refractory type 1 autoimmune hepatitis with methotrexate. J Hepatol 1998; 29: 990-3.
142. Kanzler S, Gerken G, Dienes HP,. Meyer zum Büschenfelde KH, Lohse AW. Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis-report of three cases. Z Gastroenterol 1997; 35: 571-8.
143. Langley PG, Underhill J, Tredger JM, et al,. Thiopurine methyltransferase phenotype and genotype in relation to azathioprine therapy in autoimmune hepatitis. J Hepatol 2002; 37: 441-7.
144. Heneghan MA, Allan ML, Bornstein JD, et al,. Utility of thiopurine methyltransferase genotyping and phenotyping, and measurement of azathioprine metabolites in the management of patients with autoimmune hepatitis. J Hepatol 2006; 45: 584-91.
145. Czaja AJ, Carpenter HA,. Thiopurine methyltransferase deficiency and azathioprine intolerance in autoimmune hepatitis. Dig Dis Sci 2006; 51: 968-75.
146. Vogel A, Heinrich E, Bahr MJ, et al,. Long-term outcome of liver transplantation for autoimmune hepatitis. Clin Transplant 2004; 18: 62-9.
147. Cross TJ, Antoniades CG, Muiesan P, et al,. Liver transplantation in patients over 60 and 65 years: an evaluation of long-term outcomes and survival. Liver Transpl 2007; 13: 1382-8.
148. Montano-Loza AJ, Mason AL, Ma M, Bastiampillai RJ, Bain VG, Tandon P,. Risk factors for recurrence of autoimmune hepatitis after liver transplantation. Liver Transpl 2009; 15: 1254-61.